RxDoctor Payments Data

Francis Gialanella, MD

Internal Medicine · Orange, NJNPI 1265448237

Payments from drug & device makers

$29,219in general payments, 2019–2025

Across 1,747 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$5K
  • AbbVie$3K
  • Amgen$2K
  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$29,03399%
  • Education$1861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk325$4,878
AbbVie(2 entities)202$3,165
Amgen(2 entities)115$2,306
Boehringer Ingelheim113$2,248
AstraZeneca96$2,042
Lilly USA, LLC107$1,517
Pfizer109$1,371
Johnson & Johnson38$1,275
Bayer58$1,019
Merck66$960
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC52$753
Novartis56$741
Sanofi-aventis U.S. LLC34$693
Amarin Pharma, Inc.44$638
Idorsia Pharmaceuticals US Inc23$453
Daiichi Sankyo Inc.30$428
Dexcom, Inc.23$415
Kowa Pharmaceuticals America, Inc.29$411
Astellas Pharma US Inc18$385
Ardelyx, Inc.20$349
Eisai Inc.18$280
GSK19$279
Exact Sciences9$229
Azurity Pharmaceuticals, Inc.10$172
Scilex Pharmaceuticals Inc.12$167
Teleflex LLC1$149
Ironwood Pharmaceuticals, Inc10$135
Abbott6$132
Esperion Therapeutics, Inc.8$125
Corcept Therapeutics6$124
Hikma Pharmaceuticals USA8$115
Takeda Pharmaceuticals U.S.A., Inc.7$114
E.r. Squibb & Sons, L.L.C.6$94
Intra-sana Laboratories6$91
Teva Pharmaceuticals USA, Inc.6$90
Biohaven Pharmaceutical Holding Company Ltd.5$71
Antares Pharma, Inc.4$70
Arbor Pharmaceuticals, Inc.5$68
Almatica Pharma LLC4$62
Nestle Healthcare Nutrition Inc.4$59
Nabriva Therapeutics, PLC4$51
Xeris Pharmaceuticals, Inc.3$48
Sanofi Pasteur Inc.3$48
Genentech USA, Inc.3$40
Phadia US Inc.2$40
Insulet Corporation2$40
C2n Diagnostics, LLC2$35
Aimmune Therapeutics, Inc.2$34
Phathom Pharmaceuticals, Inc.2$32
Biohaven Pharmaceuticals, Inc.2$26
Medtronic1$19
Amphastar Pharmaceuticals, Inc.1$19
UCB, Inc.1$18
Sumitomo Pharma America, Inc.1$16
Eyevance Pharmaceuticals LLC1$15
Vanda Pharmaceuticals Inc.1$15
Sebela Pharmaceuticals Inc.1$15
Gilead1$13
Regeneron Healthcare Solutions, Inc.1$12
Metuchen Pharmaceuticals1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,219 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$117,157
Medicare patients
399
Services billed
1,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin192$201,822
EliquisApixaban181$124,213
OzempicSemaglutide119$115,377
JanuviaSitagliptin Phosphate95$85,018
XareltoRivaroxaban67$66,578
FarxigaDapagliflozin Propanediol87$65,323
MounjaroTirzepatide55$64,104
RybelsusSemaglutide31$54,110
AtivanLorazepam13$53,710
LinzessLinaclotide90$51,566
CreonLipase/Protease/Amylase26$49,486
TrulicityDulaglutide30$29,814
Janumet XrSitagliptin Phos/Metformin Hcl45$29,016
JanumetSitagliptin Phos/Metformin Hcl17$28,819
MyrbetriqMirabegron36$26,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr, Glyxambi$2,248$260,204252 claims
Novo NordiskOzempic, Rybelsus, Wegovy$4,878$184,792161 claims
MerckJanuvia, Janumet Xr, Janumet$960$142,853157 claims
PfizerEliquis, Premarin$1,371$130,213199 claims
AbbVieLinzess, Creon$3,165$101,052116 claims
AstraZenecaFarxiga, Breztri Aerosphere, Crestor$2,042$95,257124 claims
Lilly USA, LLCMounjaro, Trulicity$1,517$93,91785 claims
Johnson & JohnsonXarelto$1,275$66,57867 claims
GSKTrelegy Ellipta, Breo Ellipta$279$36,45664 claims
Astellas Pharma US IncMyrbetriq$385$26,76636 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$693$21,48112 claims
NovartisEntresto$741$20,36819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →